Patients with metastatic colorectal cancer are usually offered systemic chemotherapy as palliative treatment. A multivariate analysis was performed in order to identify predictors and their constellation that allow a valid prediction of the outcome in patients treated with 5-fluorouracil (5-FU)-based therapy.
Introduction
Cancer of the large intestinum is one of the leading causes of cancer deaths in elderly men and women [1] . Approximately 50% of patients will eventually die due to metastatic spread of their disease. Compared with patients receiving best supportive care only, chemotherapy prolongs the median survival of patients with metastatic disease [2] . Therefore, palliative chemotherapy is offered to these patients to ameliorate symptoms, preserve the quality of life and improve survival.
Clinical trials, although using similar patient selection criteria, often display a surprising heterogeneity in survival rates [3] , which is usually explained by differences in patient characteristics or prognostic factors. Patients entering randomised trials are usually stratified according to their performance status, but in addition other prognostic factors or their constellation may have the potential to determine the survival of patients to a greater extent than any promising antineoplastic agent or drug combination.
A variety of clinical parameters such as performance status [4] , elevated lactate dehydrogenase, white blood cell (WBC) count [5] , serum albumin [4] , elevated liver transaminases [6] , level of haemoglobin [7] or platelets, pathological grading [8] or localisation of the primary [9] , or tumour markers like carcinoembryonic antigen (CEA) [8] have been identified as prognostic markers in some studies that seldom included more than 400 patients. There is no consensus and general acceptance about the importance of various prognostic factors. We collected a large database of patients with metastatic colorectal cancer who were eligible for clinical trials and treated with a 5-fluorouracil (5-FU)-based regimen, in order to identify predictors and their constellation that would classify patients according to their predictor values into a few clearly separated groups with different risks.
Materials and methods

Data collection
European study coordinators of large clinical trials were contacted and source data of 3825 patients from 19 randomised and three phase II studies were collected [7, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . The trials recruited patients from 1982 until 1996 (Table 1) and investigated different 5-FU-based schedules. Data for each study were checked for consistency after transformation to the main database.
Three trials compared 5-FU/leukovorin against raltitrexed [27] [28] [29] , but only patients who received the 5-FU-containing arm were selected for the analysis. All trials are listed in Table 1 . The variables were grouped into laboratory, tumour or clinical parameters. The cut points for laboratory parameters were chosen as above or lower normal limits and arbitrarily at other values (Table 2) .
Statistical analysis
Tree analysis. A tree analysis approach was used to analyse the relations between the predictor variables and the outcome, the total survival. Recursive partition and amalgamation (RECPAM) is especially designed for this situation [30] . In this methodology the patient population is recursively partitioned into subgroups, the 'nodes'. Each split is defined by the value of one selected predictor. At each step, among all candidates the predictor with the highest power to discriminate between good and bad survival is chosen. As a result, each terminal node is characterised by a set of predictors and their values and is simultaneously associated with a distinct survival curve. Terminal nodes derived from different parent nodes may have similar survival curves and are finally amalgamated. The resulting clusters should define classes of patients with clearly separated survival curves.
We preferred RECPAM over the classical Cox's regression [31] approach for the following reasons: (i) RECPAM is directly focussed on the derivation and characterisation of clearly separable risk classes rather than on fitting regression equations to the data.
(ii) Interactions between the predictors, if present in the data, are entered automatically into the model. (iii) Missing values of active predictors are replaced by surrogate variables in a special way, newly adapted for each node. Thus all patients may contribute to the derivation of the model. (iv) Internal validation is incorporated into the model by applying pruning techniques and the Akaike Information Criterion (AIC) as an approximate cross-validation procedure. It was applied to select the tree with the smallest AIC as the 'best honest tree', but also to select the simplest acceptable tree by applying the 'elbow rule' to the curve of AIC versus number of nodes within the pruning procedure [30] . Thus, prediction bias due to over-fitting is generally avoided. External validation. In order to add an external validation to the analyses, we split the population randomly into a learning (n = 2541) and a validation (n = 1276) set. The RECPAM prediction model was derived using only the learning set and it was then applied to the independent validation set. Thus the predicted survival curves within the validation clusters could be compared with the observed curves. Details of the RECPAM approach. The prediction model was derived in two steps: first a RECPAM subtree was derived for each of the abovementioned subset of predictors (clinical, tumour-related and laboratory parameters). In the second step, only those parameters that were selected for the subtrees (the 'winners') were chosen as candidates for the general model. By this restriction the possibility of over-fitting was further diminished. In addition, the results of the subtree models are of interest in their own right.
The RECPAM method itself was applied with the following restrictions: the minimal node size was set to 50 patients throughout the tree, and at each node only those variables with <33% missing values were accepted for the next split. Table 3 displays the results of the univariate analyses for the whole cohort of patients. Due to the large number of patients, statistical significance is not equivalent to clinical relevance. Nevertheless, notable are those parameters that, despite of the large number of patients, were not found to be significant: age and whether the patients had received adjuvant chemotherapy. However, the number of patients who had received adjuvant chemotherapy was low (n = 277) and information about the time-span between the adjuvant chemotherapy and initiation of treatment for metastatic disease is unknown. 
Results
Univariate analyses
Multivariate analysis for subgroups of predictors
Among the clinical variables only the ECOG performance status (0, 1 versus >1) remained an independent predictor for survival in the multivariate setting, and patients with a better performance status had a better survival. For the tumour-related parameters the number of tumour sites of more than one and also of more than two, and presence of liver metastases or peritoneal carcinomatosis predicted a worse patient outcome. In contrast, in well-defined subpopulations, presence of lung or lymph node metastases and rectal cancer as the primary tumour were all associated with a better outcome. Among the laboratory parameters, platelets >400 × 10 9 /l, alkaline phosphatase of >300 U/l, WBC count >10 × 10 9 /l and haemoglobin <11 g/dl all predicted an inferior survival probability. The winners of each subgroup analysis were entered into the general predictive model.
General predictive model
The general model without amalgamation is displayed in Figure 1 and Table 4 . With the knowledge of eight different parameters the individual prognosis of a patient can be estimated, ranging from a median of 4 months up to >16 months.
The strongest predictor for survival is the performance status. The number of involved tumour sites is separating the cohort learning sample at seven of 15 possible nodes, thus indicating the importance of tumour load for the prognosis of patients with metastatic colorectal cancer. The WBC count (cut point at 10 × 10 9 /l), location of the primary tumour, level of alkaline phosphatase (cut point of 300 U/l), platelets (cut point of 400 × 10 9 /l), haemoglobin (cut point of 11 × 10 9 /l), and presence of peritoneal involvement all entered the general model and influence the prognosis at various nodes in various constellations with other parameters. Figure 1 also suggests that certain terminal nodes have a similar outcome, with one group of poor survival ranging from 4 to ∼7 months, one intermediate group ranging from ∼8 to 10 months, and one lower risk group with range of survival from 12 to 16 months. Therefore, in a further step, the evaluation was focussed on the selection of the simplest acceptable tree (by applying the above mentioned elbow rule to the AIC criterion). This was followed by the amalgamation procedure that was limited to result in only three prognostic groups that could clearly separate the patient prognosis ( Figure 2 ). With the knowledge of the four parameters-performance status, number of involved tumour sites, WBC count and alkaline phosphatase-the patients are separated into three clearly dis- In patients with a good performance status but two or more tumour sites, the level of alkaline phosphatase predicted a median survival of either 6.1 or 10.7 months. Also, in patients with a poor performance status but a normal WBC count, the number of metastatic sites predicts a median survival of 6.1 months as opposed to 10.7 months. Figure 3 shows the survival curves of the three different risk groups for the learning and validation samples. In both samples the three risk groups are clearly separated with a high level of concordance. Also, the survival curves for the good, intermediate and high risk groups of the validation set lie within the 95% confidence limits of the learning set for the first 24 months at least. The P value for the three risk goups in the validation set is <0.0001.
Discussion
To our knowledge this multivariate analysis presents the largest study to identify clinical prognostic factors for patients with metastatic colorectal cancer treated with 5-FU-based chemotherapy. We used 23 variables, of which some entered the model at different cut off points. The statistical methodology was able to identify those cut off points with the best predictive value and also potential interactions between prognostic factors. Based on a total of eight clinical parametersperformance status, number of involved tumour sites, WBC count, alkaline phosphatase, platelets, haemoglobin, presence of peritoneal carcinomatosis and location of primary tumour-the median survival for an individual patient may be estimated, ranging from 4 to 16.3 months. The evaluation of the eight parameters usually belongs to the clinical routine before a patient receives chemotherapy. In order to generate a more simplified model, patient risk groups with similar outcomes were combined and three clearly separated risk groups were defined. With the use of only four clinical parameters, i.e. performance status, level of WBC count, alkaline phosphatase and number of involved tumour sites, a high risk group with a median survival of 6.1 months, an intermediate risk group with a median survival of 10.7 months and a low risk group with a median survival of 15 months were identified. About 21% of the patients in our validation set belonged to the high risk, 35% into the intermediate and 44% into the low risk group. Whether this actually reflects the population regularly seen in oncology clinics or rather a typical population entering clinical trials is unknown.
Earlier attempts to identify prognostic factors identified variables consistent to our findings. Most investigators reported the performance status [5, 8, [32] [33] [34] as a major prognostic factor, but the WBC count (10 × 10 9 /l) [5, 35, 36] , haemoglobin [6] , alkaline phosphatase [5] and site of the primary tumour (i.e. colon or rectum) [9] were also identified by some.
Our general model, however, has some limitations. In approximately two-thirds of cases we had no information on weight loss, level of lactate dehydrogenase (LDH), serum protein, albumin or pathological tumour grading. In addition, in ∼50% of patients information on bilirubin, transaminases, CEA levels and tumour-related symptoms were missing. Serum levels of LDH, CEA, bilirubin transaminases and albumin and weight loss were all identified as prognostic factors in smaller cohorts of patients [5, 8, 32, [37] [38] [39] . The RECPAM analysis uses surrogate markers in case of missing values in certain patients. This is a useful tool in order not to exclude too many patients with missing values or alternatively not too exclude too many variables from the analysis. We determined that no variables should have >33.3% of patients with missing values within a node that separates the population by this variable. Hence, all variables with a moderate (50%) or high (75%) rate of missing value still had a chance to enter the model; however, the likelihood was lower compared with the chances of other variables, unless they had a marked impact on prognosis.
Any multivariate analysis faces the problem that only those variables that have been put into the model come out as important predictors. It is possible that other potential parameters or constellation of variables may better describe and separate the prognosis of patients with metastatic colorectal cancer. Nevertheless, our learning sample clearly identifies three separated risk groups validated in the validation set. Whether other variables including those with a high rate of missing values might add any information to our model remains speculative and at present less important, as we were able to clearly separate patient risk groups with the available data. The difference in median survival in the three groups is also of definite clinical relevance. Our model was based on patients who received several forms of 5-FU-based treatment, i.e. bolus 5-FU, 5-FU with modulation or infusional 5-FU regimens. Whether this model also applies to patients receiving 5-FU in combination with CPT-11 or oxaliplatin as their first-line treatment is unknown. In other words, it may by speculated that a more effective treatment may alter the predictive value of prognostic factors. Interestingly, the number of involved organ sites, performance status and WBC count have all been identified as important prognostic factors in a recent randomised trial with the use of CPT-11 and 5-FU as first-line treatment [39] . Also, two studies with the use of 5-FU in combination with oxaliplatin found the number of involved organ sites, performance status and alkaline phosphatase as independent prognostic factors consistent with our findings [40] . In addition, similar results have been reported in two studies for patients receiving CPT-11 as second-line treatment after 5-FU failure [41, 42] . In a multivariate Cox's regression analysis performance status, haemoglobin, WBC count and alkaline phosphatase were identified in both studies and number of involved tumour sites, aspartate aminotransferase and right-sided primary tumours of the colon in at least one of these two trials. In summary, the prognostic factors identified within our model appear to be a consistent finding, irrespective of the type of cytostatic treatment and whether patients receive first-or second-line therapy.
What are the potential implications of our findings?
First, our three risk groups could serve as a useful stratification tool for clinical trials. Four parameters separate patient survival by a median of ∼5 months. Indeed, very often multivariate analysis performed in controlled randomised trials demonstrates a larger influence on survival for certain prognostic factors than for the treatment that was under investigation [19, 39, 43] . This is of special importance as most clinical trials demonstrate only a small difference, if any at all, in median survival, which seldom exceeds 2-3 months.
Secondly, to use the four variables for a more precise description of patients entering non-randomised trials also appears useful. Patients entering phase II trials may often represent a more favourable subgroup. Thus, a median survival of 12 months in a patient cohort that belongs to the high risk category may be very promising, but more disappointing for a low risk group. Thirdly, our model allows for an estimate of expected individual patient survival, and every fifth patient in our population had a a median survival of only ∼6 months, despite receiving 5-FU-based treatment. Prospective trials should answer the question of whether this high risk group of patients might benefit from a more intensive first-line treatment. Preliminary retrospective data, presented by Knight et al. [44] , indicate the opposite, namely that patients with a favourable prognostic profile, rather than those with a poor one identified by levels of LDH, did benefit more from intensified treatment. Nevertheless, only a prospective randomised trial would help to identify the groups of patients that benefit most from intensified combination treatment with CPT-11 or oxaliplatin added to modulated 5-FU.
Fourthly, the level of haemoglobin has also been identified by the Nordic Group as a risk factor. Recently, trials using erythropoietin to increase the haemoglobin level suggest the possibility of an improved outcome for patients with haematological malignancies and solid tumours receiving erythropoietin in addition to chemotherapy [45, 46] . Our investigation implies that further study of the effects of erythropoietin in patients with metastatic colorectal cancer and low haemoglobin levels is necessary.
Finally, markers identified as predictors of response to chemotherapy such as thymidilate synthetase or thymidine phosphorylase [47, 48] , or molecular prognostic parameters for survival, such as proteins involved in the cell cycle regulation and apoptosis [49] , should be validated against our simple model, as all of them need sophisticated and expensive laboratory investigations and thus are less easily obtained compared with our simple clinical parameters.
In summary, patients with metastatic colorectal cancer are very heterogeneous in respect to survival after a standard cytostatic drug treatment. Patients entering randomised trials for metastatic colorectal cancer may be stratified by at least four simple parameters. Also, the EORTC GI group will initiate studies for high risk, intermediate and low risk patients separately. Our model may serve as a point of reference for any other models using different parameters.
